Hadlima – also known as SB5 – was one of several Humira biosimilars that launched in the US on or after 1st July, when AbbVie's patent protection for Humira (adalimumab) finally expired.

So far, the only high-concentration Humira biosimilar with FDA approval is Samsung Bioepis and Organon's Hadlima HC, which is expected to launch in the summer. Additionally, all of the FDA ...

The South Korean drugmaker added that Hyrimoz and Hadlima, Humira biosimilars marketed by CVS Health (CVS)/Sandoz (SDXNY) (OTCQX:SDZXF) and Organon (OGN)/Samsung Bioepis, respectively, have led to ...

In its place, the PBM included the Humira-referenced biosimilars Hyrimoz, Hadlima and adalimumab-fkjp (an unbranded product). Hyrimoz appears to be the most favored biosimilar. While removal of ...

Last week Samsung Bioepis and Organon announced FDA approval of their citrate-free, high-concentration (100 mg/ml) HUMIRA biosimilar, HADLIMA (adalimumab-bwwd). HADLIMA was previously approved by ...